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Resumen:
La lucha contra el cáncer es aún un desafío mayor, con cerca de 14 millones de nuevos casos 
de cáncer al año y más de 8 millones de muertes anuales atribuidas al cáncer. Con la ayuda 
de múltiples servicios clínicos del HUMV y otras Instituciones, trabajamos para demostrar la 
hipótesis de que análisis integrados de genómica y secuenciación dirigida de alta profundi-
dad en especímenes quirúrgicos de rutina puede generar datos firmes y relevantes sobre la 
complejidad molecular, composición subclonal, índice mutacional, firmas mutacionales y mu-
taciones precisas en genes con implicaciones terapéuticas; así generando una herramienta 
diagnóstica robusta que permita predecir sensibilidad a terapias específicas. In este proyecto, 
hemos podido demostrar que los estudios genómicos del cáncer demuestran dianas útiles 
para la intervención terapéutica y que la combinación de múltiples terapias inactivando rutas 
oncogénicas convergentes representa una opción plausible para pacientes con cáncer avan-
zado.
Abstract:
Cancer is still a mayor challenge with something more than 14M new cases per year in the 
world and more of 8M patients dying yearly because of cancer. With the collaboration of multi-
ple clinical services at the HUMV and other clinical institutions, we are working to demonstrate 
the hypothesis that genomics integrative analysis and high-depth targeted mutational analysis 
in routine cancer specimens may generate consistent, relevant data informing about molecular 
complexity, subclonal composition, mutational rate, mutational signatures and precise muta-
tions in genes with therapeutic implications; thus generating a robust, solid, diagnostic tool 
that may allow to predict the sensitivity to specific therapies. In this project we have been able 
to demonstrate that cancer genome studies do demonstrate actionable targets, and that the 
combination of multiple therapies targeting convergent pathways represent a plausible option 
for advanced cancer patients.
Cancer challenges
Cancer is still a mayor challenge with something more than 
14M new cases per year in the world and more of 8M pa-
tients dying yearly because of cancer(1).
Progresses in cancer therapy are strictly dependent on the 
acquisition of new data on cancer molecular complexity 
and the integration of these molecular data into the clini-
copathological background of the patients. Medical and 
academical institutions along the world are trying to ela-
borate a cancer taxonomy that responds to these challen-
ges. Cancer taxonomy is the systems that allow assigning 
treatment based on the combined analysis of morphology, 
immunophenotype and molecular features of the disease. 
Final objective of this approach is a precise definition of 
clinicopathological entities leading to the identification of 
underlying molecular alterations, thus providing targets for 
therapy and predictive and prognostic markers for patient 
stratification.
Although the elaboration of this cancer taxonomy is a task 
for multiple clinical specialities and academic researchers, 
pathologists play a central role in the integration of clinical 
and molecular data and the definition of clinicopathological 
entities. 
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The explosion of cancer genomics
Moore’s Law is a computing term that originated around 
1970; the simplified version of this law states that overall 
processing power for computers will double every two 
years. Consequently the cost of tumour sequencing has 
decreased at the same speed, this making possible that 
cancer genome analysis is becoming a routine clinical 
tool. This has expanded dramatically the armamentarium 
of tools for cancer diagnosis and has made possible the 
development of ambitious international projects, like the 
International Cancer Genome Consortium (ICGC), organi-
zed to coordinate a large number of research projects that 
have the common aim of elucidating comprehensively the 
genomic changes present in multiple forms of cancers that 
contribute to the burden of disease throughout the world (2). 
The primary goals of the ICGC were to generate compre-
hensive catalogues of genomic abnormalities (somatic 
mutations, abnormal expression of genes, epigenetic mo-
difications) in tumours from 50 different cancer types and/
or subtypes which are of clinical and societal importance 
across the globe, making these data available to the re-
search community as rapidly as possible, and with minimal 
restrictions, to accelerate research into the causes and 
control of cancer. 
Currently, the ICGC has received commitments from funding 
organizations in Asia, Australia, Europe, North America and 
South America for 88 project teams in 17 jurisdictions to stu-
dy over 25,000 tumor genomes. Projects that are currently 
funded are examining tumors affecting: the biliary tract, 
bladder, blood, bone, brain, breast, cervix, colon, eye, head 
and neck, kidney, liver, lung, nasopharynx, oral cavity, ovary, 
pancreas, prostate, rectum, skin, soft tissues, stomach, 
thyroid and uterus. Results of these projects have been pu-
blished in the major scientific journals (https://icgc.org).
First results of the cancer genomics projects
New fascinating data is being quickly produced as a result 
of this and associated projects. Some of the more striking 
new data and concept emerged from this project are:
• Cancer is a multigenic disorder, with more than 
1000 mutated genes and 0-700 mutated genes per 
case(3). Thus, the idea that mutation in a limited num-
ber of genes could be responsible for common cancer 
types has now being replaced by the evidence that a 
large majority of cancer samples contain from dozens 
to hundreds of mutations in multiples genes; as a coro-
llary to this the census of cancer genes is increasing up 
to several hundreds(4). Thus, COSMIC, the Catalogue 
Of Somatic Mutations In Cancer (http://cancer.sanger.
ac.uk), the world’s most comprehensive resource for 
exploring the impact of somatic mutations in human 
cancer, described in the latest release (v70; Aug 2014) 
2 002 811 coding point mutations in over one million 
tumor samples and across most human genes(4). 
• Entities defined on a clinicopathological basis 
show an unexpected degree of molecular hetero-
geneity. As an example, in breast cancer driver muta-
tions have been found in at least 40 cancer genes and 
73 different combinations of mutated cancer genes(5) 
were identified alter genomic analysis.
• Analysis of different tumour types have shown that 
basically each tumour sample contains a uni-
que combination of mutated genes, such as been 
shown for Squamous cell Lung Cancer(6) and others. 
• There is a high degree of intratumoral heterogenei-
ty, much higher than initially expected(7). Thus, single-
cell sequencing or high-depth sequencing shows that 
tumours contain multiple subclones that compete for 
survival(8). This increased Intratumor heterogeneity can 
lead to underestimation of the tumour genomics lands-
cape obtained from single tumour-biopsy samples or 
serum DNA analysis, and present key challenges to 
personalized-medicine and biomarker development. 
• Additionally, intratumoral heterogeneity is in the 
basis of the therapeutic failure through Darwinian 
selection(9). Thus sequential analysis of tumour sam-
ples or serum DNA demonstrates that tumours dy-
namically evolve along the time, acquiring or losing 
some of the genetic events that may dictate response 
to targeted therapy. Pressure for this Darwinian chan-
ge may be partially the result of therapy contributing 
to change the equilibrium different subclones(10). Thus, 
studies in AML and other tumours demonstrate that 
relapse is associated with the appearance of new mu-
tations and clonal evolution, which is partially shaped 
by the initial chemotherapy that the patients receive 
to establish and maintain remissions(9). Thus, the pre-
sence of a subclonal driver mutation maybe an inde-
pendent risk factor for rapid disease progression(11), 
and indeed the presence of very mimor subclones at 
the diagnosis of the disease have been demonstrated 
to be an important driver of the subsequent disease 
course in CLL cases carrying p53 mutations(12).
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Figure 1: Complexity of cancer genomes can now be revealed 
through the use of Next Generation Sequencing technologies. 
Thus, now cancer exomes or targeted mutational analysis can be 
performed at a low cost and reasonable speed.
19REV MED VALDECILLA. 2015:0 (1).
• Genetic mutations are, nevertheless, not the unique 
cause of cancer. Thus, studies in pediatric tumors, 
such as ependymoma, have extremely low mutation 
rate, with none significant recurrent somatic single 
nucleotide variants, associated with a CpG island 
methylator phenotype, thus suggesting that genetic 
modifiers should be the therapeutic candidates for 
this malignancy(13).
• New hope has been brought to the field by the finding 
that immune checkpoint inhibitors, which unleash a 
patient’s own T cells to kill tumors, may indice durable 
remissions in tumours resistant to multiple lines of the-
rapy. Interestingly, higher mutational rates in tumours 
has been shown to predict a favourable response to 
these checkpoint inhibitors, thus suggesting that the 
genomic landscape of lung cancers shapes response 
to anti-PD-1 therapy(14).
Therapy driven by molecular integrative analysis, the 
purpose of the Cancer Genomics Group
In this context, with the invaluable collaboration of the On-
cology, Haematology, Pathology and other clinical servi-
ces, we are developing a project following the hypothesis 
that genomics integrative analysis and high-depth targe-
ted mutational analysis in routine cancer specimens may 
generate consistent, relevant data informing about mole-
cular complexity, subclonal composition, mutational rate, 
mutational signatures and precise mutations in genes with 
therapeutic implications; thus generating a robust, solid, 
diagnostic tool that may allow to predict the sensitivity to 
specific therapies. In this project we have been able to 
demonstrate that cancer genomes do contain actionable 
targets, and that the combination of multiple therapies tar-
geting convergent pathways represent a plausible option 
for advanced cancer patients(15-22).
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Figure 2: Cancer genomics project steps: 
A. Identification of a disease model following the integra-
tion of Gene expression, mutation and experimental 
data allow selecting a suitable opportunity for research.
B. Identification of pathways and genes to be analysed in 
routine specimens
C. The study of precise tumour sample demonstrate actio-
nable mutated genes, tumour specific targetable signa-
tures or genes
D. In vivo experiments performed in immunosuppressed 
mice (PDXs) allow to test specific drug and drug com-
binations
E. These results open the opportunity for clinical trials whe-
re to evaluate the clinical application
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